Preclinical diagnosis of Alzheimer's disease (AD) is one of the major challenges for the
prevention of AD. AD biomarkers are needed not only to reveal preclinical pathologic …

The different molecular paths that PET in-vivo biomarkers can reveal in the timeframe of
Alzheimer's disease progression reflect the events leading to deposition of Aβ and …

Alzheimer's disease (AD) affects more than 35 million people worldwide, and the number is
estimated to quadruple in 40 years if there remains no cure. 1–4 AD is characterized by the …

Alzheimer's disease (AD) is a devastating and progressive neurodegenerative disease for
which there is no cure. Mild cognitive impairment (MCI) is considered a prodromal stage of …

Molecular neuroimaging techniques such as PET are proving valuable in the early and
differential diagnosis of Alzheimer's disease (AD). With the advent of new therapeutic …

Alzheimer's disease (AD) is the leading cause of dementia, accounting for 60–70% of all
cases [Hebert et al., 2003, 1]. The need for effective therapies for AD is great. Current …

PET based tools can improve the early diagnosis of Alzheimer's disease (AD) and
differential diagnosis of dementia. The importance of identifying individuals at risk of …

The development of prevention therapies for Alzheimer's disease (AD) would greatly benefit
from biomarkers that are sensitive to subtle brain changes occurring prior to the onset of …

PET is a non-invasive imaging technique which allows the visualization and quantification of
molecular processes, offering sensitive and early disease detection. Alzheimer's disease …

Alzheimer's disease (AD) is the most common cause of dementia and accounts for
approximately 50% to 80% of all cases of dementia. The diagnosis of probable AD is based …